IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more
IMMUNOCORE HLDGS ADS/1 (6YG) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IMMUNOCORE HLDGS ADS/1 - Net Assets Trend (None–None)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IMMUNOCORE HLDGS ADS/1 (None–None)
The table below shows the annual net assets of IMMUNOCORE HLDGS ADS/1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to IMMUNOCORE HLDGS ADS/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
IMMUNOCORE HLDGS ADS/1 Competitors by Market Cap
The table below lists competitors of IMMUNOCORE HLDGS ADS/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
$1.01 Billion |
|
Universal Robina Corporation
PINK:UVRBF
|
$1.01 Billion |
|
Partner Communications Company Ltd.
PINK:PTNRF
|
$1.01 Billion |
|
Grupo Gigante S. A. B. de C. V
PINK:GPGNF
|
$1.01 Billion |
|
Vizio Holding Corp
NYSE:VZIO
|
$1.01 Billion |
|
Alliance Financial Group Bhd
KLSE:2488
|
$1.01 Billion |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
$1.01 Billion |
|
Shanghai Taisheng Wind Power
SHE:300129
|
$1.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IMMUNOCORE HLDGS ADS/1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares IMMUNOCORE HLDGS ADS/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently IMMUNOCORE HLDGS ADS/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares IMMUNOCORE HLDGS ADS/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IMMUNOCORE HLDGS ADS/1 (6YG) | €- | N/A | N/A | $1.01 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |